2026 Bruce L. Levine: Immunology Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Immunology	102	655	604	382	346	340	71365
Medicine	102	7478	7026	3910	3616	345	71381

Overview

Bruce L. Levine is affiliated with the University of Pennsylvania in the United States. Their research primarily spans the field of Medicine, with a particular emphasis on Oncology, Molecular Biology, Immunology, Physiology, and Biomedical Engineering. These subfields reflect the scientific breadth under which their work is conducted.

The main focus of Levine's work lies in CAR-T cell therapy research, with a total of 120 publications related to this topic. Other significant topics of their research include Immune Cell Function and Interaction, Biomedical Ethics and Regulation, Viral Infectious Diseases and Gene Expression in Insects, CRISPR and Genetic Engineering, Virus-based Gene Therapy Research, and Immunotherapy and Immune Responses.

Levine has published a number of research papers, notably:

"CRISPR-engineered T cells in patients with refractory cancer," 2020, Science
"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells," 2022, Nature
"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy," 2024, Nature Medicine
"Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia," 2020, Journal of Clinical Oncology
"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy," 2024, Nature Medicine

They frequently publish in the journal Cytotherapy, contributing 48 articles there, followed by publications in Blood, Nature Medicine, bioRxiv (Cold Spring Harbor Laboratory), and Blood Advances.

Among Levine's frequent co-authors are Carl H. June, J. Joseph Melenhorst, Rachele Ciccocioppo, Jaap Jan Boelens, and Miguel Forte, each having collaborated on multiple occasions. This network highlights a collaborative environment within the field of immunotherapy and related biomedical research.

Best Publications

Chimeric antigen receptor T cells for sustained remissions in leukemia.

Shannon L. Maude;Noelle Frey;Pamela A. Shaw;Richard Aplenc

6001
Citations
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude;Theodore W Laetsch;J. Buechner;S. Rives

5574
Citations
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

David L. Porter;Bruce L. Levine;Michael Kalos;Adam Bagg

4413
Citations
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Stephan A. Grupp;Michael Kalos;David Barrett;Richard Aplenc

4108
Citations
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Michael Kalos;Bruce L. Levine;David L. Porter;Sharyn Katz

3117
Citations
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Stephen J. Schuster;Jakub Svoboda;Elise A. Chong;Sunita D. Nasta

1910
Citations
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

David L. Porter;Wei-Ting Hwang;Noelle V. Frey;Simon F. Lacey

1870
Citations
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

Donald M. O’Rourke;MacLean P. Nasrallah;Arati Desai;Jan J. Melenhorst

1748
Citations
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Joseph A. Fraietta;Simon F. Lacey;Elena J. Orlando;Iulian Pruteanu-Malinici

1685
Citations
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Pablo Tebas;David Stein;Winson W. Tang;Ian Frank

1662
Citations
CRISPR-engineered T cells in patients with refractory cancer

Edward A. Stadtmauer;Joseph A. Fraietta;Megan M. Davis;Adam D. Cohen

1383
Citations
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

Gerald P. Linette;Edward A. Stadtmauer;Marcela V. Maus;Aaron P. Rapoport

1317
Citations
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Claudio G. Brunstein;Jeffrey S. Miller;Qing Cao;David H. McKenna

1225
Citations
Engineered T cells: the promise and challenges of cancer immunotherapy

Andrew D. Fesnak;Carl H. June;Bruce L. Levine

1168
Citations
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia

David T. Teachey;David T. Teachey;Simon F. Lacey;Pamela A. Shaw;J. Joseph Melenhorst

1094
Citations
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

Gregory L. Beatty;Andrew R. Haas;Marcela V. Maus;Drew A. Torigian

976
Citations
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

Aaron P Rapoport;Edward A Stadtmauer;Gwendolyn K Binder-Scholl;Olga Goloubeva

961
Citations
Use of chimeric antigen receptor-modified t cells to treat cancer

Carl H. June;Bruce L. Levine;David L. Porter;Michael D. Kalos

888
Citations
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Joseph A. Fraietta;Christopher L. Nobles;Morgan A. Sammons;Morgan A. Sammons;Stefan Lundh

863
Citations
Global Manufacturing of CAR T Cell Therapy

Bruce L. Levine;James Miskin;Keith Wonnacott;Christopher Keir

810
Citations
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

John Scholler;Troy L. Brady;Gwendolyn Binder-Scholl;Wei-Ting Hwang

766
Citations

Frequent Co-Authors

Carl H. June University of Pennsylvania

David L. Porter University of Pennsylvania

Simon F. Lacey University of Pennsylvania

Stephan A. Grupp Children's Hospital of Philadelphia

Michael Kalos Next Pillar Consulting

J. Joseph Melenhorst University of Pennsylvania

Edward A. Stadtmauer University of Pennsylvania

Michael C. Milone University of Pennsylvania

David M. Barrett Children's Hospital of Philadelphia

James L. Riley University of Pennsylvania

External Links

Personal website of Bruce L. Levine

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

For students interested in Immunology, exploring related healthcare degrees can open up diverse career opportunities. Many professionals in research, clinical, and healthcare settings often complement their immunology background with nursing credentials.

One popular option includes online RN programs for non nurses in Florida. These programs allow non-nursing graduates to fast-track their way into Registered Nurse roles, leveraging their existing scientific knowledge.

Accelerated pathways like accelerated nursing programs provide an efficient route for those holding bachelor’s degrees in other fields to gain nursing credentials quickly, offering a strong clinical foundation relevant to immunology careers.

For those seeking entry-level nursing qualifications, lpn programs easy to get into offer accessible options that serve as stepping stones toward advanced roles in healthcare and immunology research support.

Lastly, pursuing advanced practice roles through what is the easiest NP program can lead to specialized career tracks combining clinical expertise with immunological knowledge, ideal for those aiming to contribute directly to patient care and immunotherapy development.